|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0042769,
umls-concept:C0087111,
umls-concept:C0150369,
umls-concept:C0220847,
umls-concept:C0332466,
umls-concept:C0474643,
umls-concept:C0871261,
umls-concept:C1305923,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-7-19
|
|
pubmed:abstractText |
To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in x 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-alpha treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-alpha treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis C Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis C Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/NS3 protein, hepatitis C virus,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Core Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Nonstructural Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a,
http://linkedlifedata.com/resource/pubmed/chemical/nucleocapsid protein, Hepatitis C...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1011-8934
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
165-70
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10331562-Adult,
pubmed-meshheading:10331562-Aged,
pubmed-meshheading:10331562-Female,
pubmed-meshheading:10331562-Genotype,
pubmed-meshheading:10331562-Hepacivirus,
pubmed-meshheading:10331562-Hepatitis C,
pubmed-meshheading:10331562-Hepatitis C Antibodies,
pubmed-meshheading:10331562-Hepatitis C Antigens,
pubmed-meshheading:10331562-Humans,
pubmed-meshheading:10331562-Immunoblotting,
pubmed-meshheading:10331562-Interferon-alpha,
pubmed-meshheading:10331562-Male,
pubmed-meshheading:10331562-Middle Aged,
pubmed-meshheading:10331562-RNA, Viral,
pubmed-meshheading:10331562-Recombinant Fusion Proteins,
pubmed-meshheading:10331562-Recombinant Proteins,
pubmed-meshheading:10331562-Viral Core Proteins,
pubmed-meshheading:10331562-Viral Nonstructural Proteins
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
|
|
pubmed:affiliation |
Department of Internal Medicine, Kangnam St. Mary's Hospital, Seoul, Korea. ympark@cmc.cuk.ac.kr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
